Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2006; 12(41): 6639-6645
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6639
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6639
Parameter | Sham | BDL | P | ||
Placebo n = 9 | V-PYRRO/NO n = 12 | Placebo n = 12 | V-PYRRO/NO n = 10 | ||
Urea (mmol/L) | 10.2 ± 2.1 | 7.9 ± 1.7 | 9.2 ± 1.6 | 9.5 ± 2.7 | NS |
Creatinine (μmol/L) | 77 ± 25 | 63 ± 24 | 66 ± 11 | 73 ± 18 | NS |
AST (UI/L) | 172 ± 52 | 123 ± 60 | 1150 ± 1480a | 1164 ± 1349c | < 0.0001 |
ALT (UI/L) | 48 ± 18 | 55 ± 36 | 88 ± 47 | 82 ± 20 | NS |
Alkaline phosphatases (UI/L) | 160 ± 103 | 148 ± 80 | 380 ± 197a | 367 ± 141c | < 0.001 |
Bilirubin (μmol/L) | 1.0 ± 0.0 | 1.3 ± 0.5 | 117.0 ± 22.0a | 101.0 ± 30.0c | < 0.0001 |
- Citation: Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, Oberti F, Douay O, Gallois Y, Bonnefont-Rousselot D, Rousselet MC, Calès P. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006; 12(41): 6639-6645
- URL: https://www.wjgnet.com/1007-9327/full/v12/i41/6639.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i41.6639